C-reactive protein is associated with distant metastasis of T3 colorectal cancer

Anticancer Research

Volumn 32, Issue 4, 2012, Pages 1409-1415

  Ishizuka, Mitsuru ^a   Nagata, Hitoshi ^a   Takagi, Kazutoshi ^a   Kubota, Keiichi ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Albumin; C reactive protein; Colorectal cancer; Distant metastasis; Glasgow prognostic score; Systemic inflammatory response; T3 colorectal cancer

Indexed keywords

C REACTIVE PROTEIN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN;

AGED; ARTICLE; COLORECTAL CANCER; DISEASE ASSOCIATION; DISTANT METASTASIS; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TUMOR DIFFERENTIATION;

AGED; C-REACTIVE PROTEIN; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; NEOPLASM METASTASIS; RETROSPECTIVE STUDIES;

EID: 84860002867     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Ishizuka M, Nagata H, Takagi K and Kubota K: Systemic inflammatory response associated with distant metastasis of T1 or T2 colorectal cancer. Dig Dis Sci 55: 3181-3187, 2010.
2. McMillan DC, Elahi MM, Sattar N, Angerson WJ, Johnstone J and McArdle CS: Measurement of the systemic inflammatory response predicts cancer-specific and non-cancer survival in patients with cancer. Nutr Cancer 41: 64-69, 2001. (Pubitemid 34666222)
3. Forrest LM, McMillan DC, McArdle CS, Angerson WJ and Dunlop DJ: Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable nonsmall-cell lung cancer. Br J Cancer 90: 1704-1706, 2004. (Pubitemid 38725637)
4. Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dagg K and Scott HR: A prospective longitudinal study of performance status, an inflammation-based score (GPS) and survival in patients with inoperable non-smallcell lung cancer. Br J Cancer 92: 1834-1836, 2005. (Pubitemid 40826128)
5. Ara T and Declerck YA: Interleukin-6 in bone metastasis and cancer progression. Eur J Cancer 46: 1223-1231, 2010.
6. Al Murri AM, Bartlett JM, Canney PA, Doughty JC, Wilson C and McMillan DC: Evaluation of an inflammation-based prognostic score (GPS) in patients with metastatic breast cancer. Br J Cancer 94: 227-230, 2006. (Pubitemid 43151540)
7. Ramsey S, Lamb GW, Aitchison M, Graham J and McMillan DC: Evaluation of an inflammation-based prognostic score in patients with metastatic renal cancer. Cancer 109: 205-212, 2007. (Pubitemid 46106235)
8. Brown DJ, Milroy R, Preston T and McMillan DC: The relationship between an inflammation-based prognostic score (Glasgow Prognostic Score) and changes in serum biochemical variables in patients with advanced lung and gastrointestinal cancer. J Clin Pathol 60: 705-708, 2007. (Pubitemid 46975230)
9. McMillan DC: An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer. Proc Nutr Soc 67: 257-262, 2008.
10. Roxburgh CS and McMillan DC: Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol 6: 149-163, 2010.
11. McMillan DC: Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr Metab Care 12: 223-226, 2009.
12. Reiter W, Stieber P, Reuter C, Nagel D, Lau-Werner U, Pahl H and Fateh-Moghadam A: Preoperative serum levels of CEA and CA 19-9 and their prognostic significance in colorectal carcinoma. Anticancer Res 17: 2935-2938, 1997. (Pubitemid 27434824)
13. Reiter W, Stieber P, Reuter C, Nagel D, Lau-Werner U and Lamerz R: Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer. Anticancer Res 20: 5195-5198, 2000. (Pubitemid 32319106)
14. Japanese Classification of Colorectal Carcinoma (Japanese Society for Cancer of the Colon and Rectum, Second English Edition).
15. Wang JY, Lu CY, Chu KS, Ma CJ, Wu DC, Tsai HL, Yu FJ and Hsieh JS: Prognostic significance of pre- and postoperative serum carcinoembryonic antigen levels in patients with colorectal cancer. Eur Surg Res 39: 245-250, 2007. (Pubitemid 47000372)
16. Balkwill F and Mantovani A: Inflammation and cancer: Back to Virchow? Lancet 357: 539-545, 2001. (Pubitemid 32173595)
17. ten Kate M, Hofland LJ, van Koetsveld PM, Jeekel J and van Eijck CH: Pro-inflammatory cytokines affect pancreatic carcinoma cell. Endothelial cell interactions. J Pancreas 7: 454-464, 2006. (Pubitemid 44420472)
18. Engel A, Mack E, Kern P and Kern WV: An analysis of interleukin-8, interleukin-6 and C-reactive protein serum concentrations to predict fever, gram-negative bacteremia and complicated infection in neutropenic cancer patients. Infection 26: 213-221, 1998. (Pubitemid 28388878)
19. Herrmann JL, Blanchard H, Brunengo P and Lagrange PH: TNF alpha, IL-1 beta and IL-6 plasma levels in neutropenic patients after onset of fever and correlation with the C-reactive protein (CRP) kinetic values. Infection 22: 309-315, 1994.
20. Lehrnbecher T, Venzon D, de Haas M, Chanock SJ and Kuhl J. Assessment of measuring circulating levels of interleukin-6, interleukin-8, C-reactive protein, soluble Fc gamma receptor type III, and mannose-binding protein in febrile children with cancer and neutropenia. Clin Infect Dis 29: 414-419, 1999. (Pubitemid 29380209)
21. McArdle PA, Canna K, McMillan DC, McNicol AM, Campbell R and Underwood MA: The relationship between T-lymphocyte subset infiltration and survival in patients with prostate cancer. Br J Cancer 91: 541-543, 2004. (Pubitemid 39093576)
22. Miki C, Konishi N, Ojima E, Hatada T, Inoue Y and Kusunoki M: C-reactive protein as a prognostic variable that reflects uncontrolled up-regulation of the IL-1 IL-6 network system in colorectal carcinoma. Dig Dis Sci 49: 970-976, 2004. (Pubitemid 39012280)
23. Canna K, McArdle PA, McMillan DC, McNicol AM, Smith GW, McKee RF and McArdle CS: The relationship between tumour T-lymphocyte infiltration, the systemic inflammatory response and survival in patients undergoing curative resection for colorectal cancer. Br J Cancer 92: 651-654, 2005. (Pubitemid 40460599)
24. Shimada H, Nabeya Y, Okazumi S, Matsubara H, Shiratori T, Aoki T, Sugaya M, Miyazawa Y, Hayashi H, Miyazaki S and Ochiai T: Elevation of preoperative serum C-reactive protein level is related to poor prognosis in esophageal squamous cell carcinoma. J Surg Oncol 83: 248-252, 2003. (Pubitemid 36936011)
25. Guillem P and Triboulet JP: Elevated serum levels of C-reactive protein are indicative of a poor prognosis in patients with esophageal cancer. Dis Esophagus 18: 146-150, 2005. (Pubitemid 41801107)
26. Deans DA, Wigmore SJ, Gilmour H, Paterson-Brown S, Ross JA and Fearon KC: Elevated tumour interleukin-1beta is associated with systemic inflammation: A marker of reduced survival in gastro-oesophageal cancer. Br J Cancer 95: 1568-1575, 2006. (Pubitemid 44863361)
27. Gerhardt T, Milz S, Schepke M, Feldmann G, Wolff M, Sauerbruch T and Dumoulin FL: C-Reactive protein is a prognostic indicator in patients with perihilar cholangiocarcinoma. World J Gastroenterol 12: 5495-5500, 2006. (Pubitemid 44501808)
28. Erlinger TP, Platz EA, Rifai N and Helzlsouer KJ: C-Reactive protein and the risk of incident colorectal cancer. JAMA 291: 585-590, 2004. (Pubitemid 38500312)
29. Gunter MJ, Stolzenberg-Solomon R, Cross AJ, Leitzmann MF, Weinstein S, Wood RJ, Virtamo J, Taylor PR, Albanes D and Sinha R: A prospective study of serum C-reactive protein and colorectal cancer risk in men. Cancer Res 66: 2483-2487, 2006.
30. Wong VK, Malik HZ, Hamady ZZ, Al-Mukhtar A, Gomez D, Prasad KR, Toogood GJ and Lodge JP: C-Reactive protein as a predictor of prognosis following curative resection for colorectal liver metastases. Br J Cancer 96: 222-225, 2007. (Pubitemid 46160625)
31. O'Gorman P, McMillan DC and McArdle CS: Prognostic factors in advanced gastrointestinal cancer patients with weight loss. Nutr Cancer 37: 36-40, 2000. (Pubitemid 30650664)
32. Dixon MR, Haukoos JS, Udani SM, Naghi JJ, Arnell TD, Kumar RR and Stamos MJ: Carcinoembryonic antigen and albumin predict survival in patients with advanced colon and rectal cancer. Arch Surg 138: 962-966, 2003. (Pubitemid 37099870)
33. O'Gorman P, McMillan DC and McArdle CS: Longitudinal study of weight, appetite, performance status, and inflammation in advanced gastrointestinal cancer. Nutr Cancer 35: 127-129, 1999. (Pubitemid 30115122)
34. Al-Shaiba R, McMillan DC, Angerson WJ, Leen E, McArdle CS and Horgan P: The relationship between hypoalbuminaemia, tumour volume and the systemic inflammatory response in patients with colorectal liver metastases. Br J Cancer 91: 205-207, 2004. (Pubitemid 39037059)
35. McMillan DC, Crozier JE, Canna K, Angerson WJ and McArdle CS: Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer. Int J Colorectal Dis 22: 881-886, 2007. (Pubitemid 46952036)